| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc43b3d07e364703e2be8f6be9e94abd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d956e45fd3a544f56cfecf86847b21f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b6d97e4cc4948ae8f9d33351240a250
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e59941be132aa0cd1dc57375b9aaf23 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2009-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_647edfcc05e007c9ba1dee6def0b869b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08821a71bd61535bc55ab73c94322e37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abac2cdf3947af9b30091766ffd7c281
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7049bcb56bfc2010ac5fcae8e0b5b926 |
| publicationDate |
2011-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011166204-A1 |
| titleOfInvention |
Oligonucleotides targeting human endogenous retrovirus 9 (erv-9) long terminal repeat (ltr) and methods of use |
| abstract |
Described herein are oligonucleotides that target the human endogenous retrovirus-9 (ERV-9) long terminal repeat (LTR). The ERV-9 LTR oligonucleotides specifically hybridize with either the coding strand or non-coding strand of ERV-9 LTR. It is disclosed herein that ERV-9 LTR oligonucleotides inhibit the proliferation of cancer cells, including breast cancer, liver cancer, prostate cancer, fibrosarcoma and myeloid cancer cells. Also described herein are methods of treating a subject diagnosed with cancer comprising administering to the subject an ERV-9 LTR oligonucleotide. In some examples, the methods further comprise administering a second therapeutic agent, such as an antisense compound or a chemotherapeutic agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019270980-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019055460-A1 |
| priorityDate |
2008-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |